Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)


  • I am upgrading Teva Pharmaceutical to “Buy” for 2024, buoyed by opioid litigation resolution and promising drugs like TEV’574.
  • Strong Q3 2023 performance, marked by revenue growth in Austedo, Ajovy, and Uzedy, and increased R&D investment.
  • TEV’574, in collaboration with Sanofi, shows significant promise in inflammatory bowel disease treatment, enhancing TEVA’s pipeline.
  • The Company’s disciplined financial management and innovative product pipeline make it a compelling buy for 2024.

Business turnaround ideas, innovation, brainstorming, inspiration and problem solving ideas. Light bulbs and coins lay on the floor.

tanit boonruen/iStock via Getty Images

At a Glance

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has emerged as a compelling investment opportunity, prompting an upgrade from “Hold” to “Buy” for 2024. This shift is driven by Teva’s successful resolution of opioid litigation, strategic

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This article aims to offer informational content and is not meant to be a comprehensive analysis of the company. It should not be interpreted as personalized investment advice with regard to "Buy/Sell/Hold/Short/Long" recommendations. The predictions and opinions expressed herein about clinical, regulatory, and market outcomes are those of the author and are rooted in probabilities rather than certainties. While efforts are made to ensure the accuracy of the information, there might be inadvertent errors. Therefore, readers are encouraged to independently verify the information. Investing in biotech comes with inherent volatility, risk, and speculation. Before making any investment decisions, readers should undertake their own research and evaluate their financial position. The author disclaims any liability for financial losses stemming from the use or reliance on the content of this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Leave a Reply

Your email address will not be published. Required fields are marked *